Iron Oxide Nanoparticle-Incorporated Mesenchymal Stem Cells for Alzheimer’s Disease Treatment

Alzheimer’s disease (AD) is a neurodegenerative disease with multifactorial pathogenesis. However, most current therapeutic approaches for AD target a single pathophysiological mechanism, generally resulting in unsatisfactory therapeutic outcomes. Recently, mesenchymal stem cell (MSC) therapy, which...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Nano letters Ročník 23; číslo 2; s. 476 - 490
Hlavní autori:	Jung, Mungyo, Kim, Hyeongseop, Hwang, Jung Won, Choi, Yejoo, Kang, Mikyung, Kim, Cheesue, Hong, Jihye, Lee, Na Kyung, Moon, Sangjun, Chang, Jong Wook, Choi, Suk-joo, Oh, Soo-young, Jang, Hyemin, Na, Duk L., Kim, Byung-Soo
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States American Chemical Society 25.01.2023
Predmet:	Aged Alzheimer Disease - metabolism Alzheimer Disease - therapy Animals Cell Differentiation Humans Magnetic Iron Oxide Nanoparticles Mesenchymal Stem Cells Mice Neurodegenerative Diseases Wharton Jelly magnetic guidance Alzheimer’s disease iron oxide nanoparticles Mesenchymal stem cells
ISSN:	1530-6984, 1530-6992, 1530-6992
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Alzheimer’s disease (AD) is a neurodegenerative disease with multifactorial pathogenesis. However, most current therapeutic approaches for AD target a single pathophysiological mechanism, generally resulting in unsatisfactory therapeutic outcomes. Recently, mesenchymal stem cell (MSC) therapy, which targets multiple pathological mechanisms of AD, has been explored as a novel treatment. However, the low brain retention efficiency of administered MSCs limits their therapeutic efficacy. In addition, autologous MSCs from AD patients may have poor therapeutic abilities. Here, we overcome these limitations by developing iron oxide nanoparticle (IONP)-incorporated human Wharton’s jelly-derived MSCs (MSC-IONPs). IONPs promote therapeutic molecule expression in MSCs. Following intracerebroventricular injection, MSC-IONPs showed a higher brain retention efficiency under magnetic guidance. This potentiates the therapeutic efficacy of MSCs in murine models of AD. Furthermore, human Wharton’s jelly-derived allogeneic MSCs may exhibit higher therapeutic abilities than those of autologous MSCs in aged AD patients. This strategy may pave the way for developing MSC therapies for AD.
AbstractList	Alzheimer's disease (AD) is a neurodegenerative disease with multifactorial pathogenesis. However, most current therapeutic approaches for AD target a single pathophysiological mechanism, generally resulting in unsatisfactory therapeutic outcomes. Recently, mesenchymal stem cell (MSC) therapy, which targets multiple pathological mechanisms of AD, has been explored as a novel treatment. However, the low brain retention efficiency of administered MSCs limits their therapeutic efficacy. In addition, autologous MSCs from AD patients may have poor therapeutic abilities. Here, we overcome these limitations by developing iron oxide nanoparticle (IONP)-incorporated human Wharton's jelly-derived MSCs (MSC-IONPs). IONPs promote therapeutic molecule expression in MSCs. Following intracerebroventricular injection, MSC-IONPs showed a higher brain retention efficiency under magnetic guidance. This potentiates the therapeutic efficacy of MSCs in murine models of AD. Furthermore, human Wharton's jelly-derived allogeneic MSCs may exhibit higher therapeutic abilities than those of autologous MSCs in aged AD patients. This strategy may pave the way for developing MSC therapies for AD.Alzheimer's disease (AD) is a neurodegenerative disease with multifactorial pathogenesis. However, most current therapeutic approaches for AD target a single pathophysiological mechanism, generally resulting in unsatisfactory therapeutic outcomes. Recently, mesenchymal stem cell (MSC) therapy, which targets multiple pathological mechanisms of AD, has been explored as a novel treatment. However, the low brain retention efficiency of administered MSCs limits their therapeutic efficacy. In addition, autologous MSCs from AD patients may have poor therapeutic abilities. Here, we overcome these limitations by developing iron oxide nanoparticle (IONP)-incorporated human Wharton's jelly-derived MSCs (MSC-IONPs). IONPs promote therapeutic molecule expression in MSCs. Following intracerebroventricular injection, MSC-IONPs showed a higher brain retention efficiency under magnetic guidance. This potentiates the therapeutic efficacy of MSCs in murine models of AD. Furthermore, human Wharton's jelly-derived allogeneic MSCs may exhibit higher therapeutic abilities than those of autologous MSCs in aged AD patients. This strategy may pave the way for developing MSC therapies for AD. Alzheimer’s disease (AD) is a neurodegenerative disease with multifactorial pathogenesis. However, most current therapeutic approaches for AD target a single pathophysiological mechanism, generally resulting in unsatisfactory therapeutic outcomes. Recently, mesenchymal stem cell (MSC) therapy, which targets multiple pathological mechanisms of AD, has been explored as a novel treatment. However, the low brain retention efficiency of administered MSCs limits their therapeutic efficacy. In addition, autologous MSCs from AD patients may have poor therapeutic abilities. Here, we overcome these limitations by developing iron oxide nanoparticle (IONP)-incorporated human Wharton’s jelly-derived MSCs (MSC-IONPs). IONPs promote therapeutic molecule expression in MSCs. Following intracerebroventricular injection, MSC-IONPs showed a higher brain retention efficiency under magnetic guidance. This potentiates the therapeutic efficacy of MSCs in murine models of AD. Furthermore, human Wharton’s jelly-derived allogeneic MSCs may exhibit higher therapeutic abilities than those of autologous MSCs in aged AD patients. This strategy may pave the way for developing MSC therapies for AD. Alzheimer's disease (AD) is a neurodegenerative disease with multifactorial pathogenesis. However, most current therapeutic approaches for AD target a single pathophysiological mechanism, generally resulting in unsatisfactory therapeutic outcomes. Recently, mesenchymal stem cell (MSC) therapy, which targets multiple pathological mechanisms of AD, has been explored as a novel treatment. However, the low brain retention efficiency of administered MSCs limits their therapeutic efficacy. In addition, autologous MSCs from AD patients may have poor therapeutic abilities. Here, we overcome these limitations by developing iron oxide nanoparticle (IONP)-incorporated human Wharton's jelly-derived MSCs (MSC-IONPs). IONPs promote therapeutic molecule expression in MSCs. Following intracerebroventricular injection, MSC-IONPs showed a higher brain retention efficiency under magnetic guidance. This potentiates the therapeutic efficacy of MSCs in murine models of AD. Furthermore, human Wharton's jelly-derived allogeneic MSCs may exhibit higher therapeutic abilities than those of autologous MSCs in aged AD patients. This strategy may pave the way for developing MSC therapies for AD.
Author	Kim, Byung-Soo Kim, Hyeongseop Hwang, Jung Won Lee, Na Kyung Kim, Cheesue Chang, Jong Wook Jang, Hyemin Choi, Yejoo Jung, Mungyo Kang, Mikyung Oh, Soo-young Na, Duk L. Hong, Jihye Moon, Sangjun Choi, Suk-joo
AuthorAffiliation	Interdisciplinary Program for Bioengineering Alzheimer’s Disease Convergence Research Center Seoul National University School of Chemical and Biological Engineering Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology Institute of Chemical Processes, Institute of Engineering Research, and BioMAX Department of Obstetrics and Gynecology Cell and Gene Therapy Institute, ENCell Co., Ltd Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul National University Sungkyunkwan University Cell and Gene Therapy Institute (CGTI) Department of Neurology School of Medicine Samsung Medical Center
AuthorAffiliation_xml	– name: School of Medicine – name: Institute of Chemical Processes, Institute of Engineering Research, and BioMAX – name: Cell and Gene Therapy Institute (CGTI) – name: Samsung Medical Center – name: Sungkyunkwan University – name: Interdisciplinary Program for Bioengineering – name: Samsung Medical Center, Sungkyunkwan University School of Medicine – name: School of Chemical and Biological Engineering – name: Department of Obstetrics and Gynecology – name: Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology – name: Cell and Gene Therapy Institute, ENCell Co., Ltd – name: Department of Neurology – name: Alzheimer’s Disease Convergence Research Center – name: Seoul National University – name: Seoul National University
Author_xml	– sequence: 1 givenname: Mungyo orcidid: 0000-0001-9366-9026 surname: Jung fullname: Jung, Mungyo organization: School of Chemical and Biological Engineering – sequence: 2 givenname: Hyeongseop surname: Kim fullname: Kim, Hyeongseop organization: Cell and Gene Therapy Institute, ENCell Co., Ltd – sequence: 3 givenname: Jung Won surname: Hwang fullname: Hwang, Jung Won organization: Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology – sequence: 4 givenname: Yejoo surname: Choi fullname: Choi, Yejoo organization: Cell and Gene Therapy Institute (CGTI) – sequence: 5 givenname: Mikyung surname: Kang fullname: Kang, Mikyung organization: Seoul National University – sequence: 6 givenname: Cheesue surname: Kim fullname: Kim, Cheesue organization: School of Chemical and Biological Engineering – sequence: 7 givenname: Jihye surname: Hong fullname: Hong, Jihye organization: Seoul National University – sequence: 8 givenname: Na Kyung surname: Lee fullname: Lee, Na Kyung organization: Sungkyunkwan University – sequence: 9 givenname: Sangjun surname: Moon fullname: Moon, Sangjun organization: School of Chemical and Biological Engineering – sequence: 10 givenname: Jong Wook surname: Chang fullname: Chang, Jong Wook organization: Cell and Gene Therapy Institute, ENCell Co., Ltd – sequence: 11 givenname: Suk-joo surname: Choi fullname: Choi, Suk-joo organization: Department of Obstetrics and Gynecology – sequence: 12 givenname: Soo-young surname: Oh fullname: Oh, Soo-young organization: Department of Obstetrics and Gynecology – sequence: 13 givenname: Hyemin surname: Jang fullname: Jang, Hyemin email: hmjang57@gmail.com organization: Samsung Medical Center, Sungkyunkwan University School of Medicine – sequence: 14 givenname: Duk L. surname: Na fullname: Na, Duk L. email: dukna@naver.com organization: Samsung Medical Center, Sungkyunkwan University School of Medicine – sequence: 15 givenname: Byung-Soo orcidid: 0000-0001-5210-7430 surname: Kim fullname: Kim, Byung-Soo email: byungskim@snu.ac.kr organization: Seoul National University
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/36638236$$D View this record in MEDLINE/PubMed
BookMark	eNqFkLtOHDEUQC0ECo_kD1DkkmY2fo3XToc2BFYiUEBqy2PfEUYz9mJ7JUjFb-T38iUZtAtFilD5Sj7n6uocot2YIiB0TMmMEka_WFdm0cY0QK0z5giXiu2gA9py0kit2e7brMQ-OizlnhCieUs-oH0uJVeMywNkljlFfP0YPOCradvK5hrcAM0yupRXKdsKHv-AAtHdPY12wDcVRryAYSi4TxmfDr_uIIyQ_zz_LvhbKGAL4NsMto4Q60e019uhwKfte4R-fj-7XVw0l9fny8XpZWO5ULVRrmWdUB5AWEl1xz0DL6mY912nlVZEcUEE7zTTjPZeu773vnWMtbTn0Cp-hE42e1c5PayhVDOG4qYrbYS0LobNZTufa8HkhH7eoutuBG9WOYw2P5nXKBMgNoDLqZQM_RtCiXlpb6b25rW92baftK__aC5UW0OKNdswvCeTjfzye5_WOU61_q_8BaNNoSI
CitedBy_id	crossref_primary_10_1016_j_jpsychires_2024_09_022 crossref_primary_10_1016_j_reth_2025_07_006 crossref_primary_10_1038_s41467_024_52812_6 crossref_primary_10_1038_s41420_023_01490_2 crossref_primary_10_1039_D4BM00586D crossref_primary_10_1111_cns_70621 crossref_primary_10_1002_brx2_27 crossref_primary_10_1016_j_scib_2023_12_006 crossref_primary_10_62347_YGYM4976 crossref_primary_10_1016_j_mtbio_2025_102098 crossref_primary_10_1016_j_bioactmat_2023_09_015 crossref_primary_10_3390_s25113260 crossref_primary_10_3390_jfb15110340 crossref_primary_10_1007_s40820_025_01829_7
Cites_doi	10.3233/JAD-143120 10.3233/JAD-190817 10.1038/nature19323 10.1007/s13770-019-00226-7 10.1038/s41572-021-00269-y 10.1016/j.nantod.2015.10.001 10.1016/j.bone.2003.07.005 10.2174/15680266113139990135 10.1021/acsnano.6b02876 10.1073/pnas.1710329115 10.1038/s41573-022-00391-w 10.1007/s12035-014-9070-5 10.1016/B978-0-12-385103-1.00009-9 10.1002/adma.202207719 10.1021/acs.nanolett.8b01816 10.1155/2021/7834421 10.1007/s12272-016-0799-4 10.1016/j.bbrc.2017.08.115 10.3389/fimmu.2021.634119 10.1038/cdd.2011.140 10.1007/s12035-014-8811-9 10.1002/ame2.12207 10.1016/j.neurobiolaging.2010.03.024 10.1016/j.scr.2017.11.005 10.1186/s13287-021-02480-w 10.1007/s10238-015-0375-0 10.1038/nrdp.2015.56 10.1038/s41591-021-01455-x 10.1038/srep39340 10.1186/s13287-018-1007-x 10.1016/j.febslet.2010.07.028 10.1007/s10787-019-00613-5 10.3389/fnins.2018.00632 10.1007/s13770-019-00234-7 10.1016/S0301-472X(03)00110-3 10.1038/s41582-018-0116-6 10.3892/mmr.2020.11102 10.1002/alz.12213 10.1016/j.jconrel.2020.02.035 10.1002/adma.202106516 10.1007/s13770-019-00233-8 10.1126/sciadv.aaz0952 10.1016/j.humpath.2006.01.022 10.4161/auto.26508 10.3389/fnagi.2017.00204 10.3233/JAD-200219 10.1016/j.jalz.2010.04.006 10.1186/1742-2094-11-98 10.15283/ijsc18034
ContentType	Journal Article
Copyright	2023 American Chemical Society
Copyright_xml	– notice: 2023 American Chemical Society
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1021/acs.nanolett.2c03682
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Engineering
EISSN	1530-6992
EndPage	490
ExternalDocumentID	36638236 10_1021_acs_nanolett_2c03682 i57391457
Genre	Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- -~X .K2 123 4.4 55A 5VS 6P2 7~N AABXI ABFRP ABMVS ABPTK ABQRX ABUCX ACGFS ACS ADHLV AEESW AENEX AFEFF AHGAQ ALMA_UNASSIGNED_HOLDINGS AQSVZ BAANH CS3 DU5 EBS ED~ F5P GGK GNL IH9 IHE JG~ PK8 RNS ROL TN5 UI2 VF5 VG9 W1F AAHBH AAYXX ABBLG ABJNI ABLBI ACBEA CITATION CUPRZ CGR CUY CVF ECM EIF NPM 7X8
ID	FETCH-LOGICAL-a348t-8c52b48dee4a619b3d2ed6147fbb98980834043b92921fd9cffdd5c2251f3e583
IEDL.DBID	ACS
ISICitedReferencesCount	22
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000920395300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1530-6984 1530-6992
IngestDate	Sun Nov 09 13:17:05 EST 2025 Thu Jan 02 22:54:10 EST 2025 Sat Nov 29 04:19:59 EST 2025 Tue Nov 18 21:21:11 EST 2025 Fri Jan 27 03:10:53 EST 2023
IsPeerReviewed	true
IsScholarly	true
Issue	2
Keywords	magnetic guidance Alzheimer’s disease iron oxide nanoparticles Mesenchymal stem cells
Language	English
License	https://doi.org/10.15223/policy-029 https://doi.org/10.15223/policy-037 https://doi.org/10.15223/policy-045
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-a348t-8c52b48dee4a619b3d2ed6147fbb98980834043b92921fd9cffdd5c2251f3e583
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ORCID	0000-0001-5210-7430 0000-0001-9366-9026
PMID	36638236
PQID	2765779426
PQPubID	23479
PageCount	15
ParticipantIDs	proquest_miscellaneous_2765779426 pubmed_primary_36638236 crossref_primary_10_1021_acs_nanolett_2c03682 crossref_citationtrail_10_1021_acs_nanolett_2c03682 acs_journals_10_1021_acs_nanolett_2c03682
PublicationCentury	2000
PublicationDate	20230125 2023-01-25
PublicationDateYYYYMMDD	2023-01-25
PublicationDate_xml	– month: 01 year: 2023 text: 20230125 day: 25
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Nano letters
PublicationTitleAlternate	Nano Lett
PublicationYear	2023
Publisher	American Chemical Society
Publisher_xml	– name: American Chemical Society
References	ref9/cit9 ref45/cit45 ref3/cit3 ref27/cit27 ref16/cit16 ref23/cit23 ref8/cit8 ref31/cit31 ref2/cit2 ref34/cit34 ref37/cit37 ref20/cit20 ref48/cit48 ref17/cit17 ref10/cit10 ref35/cit35 ref19/cit19 Stokes W. S. (ref21/cit21) 2014 ref42/cit42 ref46/cit46 ref49/cit49 ref13/cit13 ref24/cit24 ref38/cit38 ref50/cit50 ref6/cit6 ref36/cit36 ref18/cit18 ref11/cit11 ref25/cit25 ref29/cit29 ref32/cit32 ref39/cit39 ref14/cit14 ref5/cit5 ref43/cit43 ref28/cit28 ref40/cit40 ref26/cit26 ref12/cit12 ref15/cit15 ref41/cit41 ref22/cit22 ref33/cit33 ref4/cit4 ref30/cit30 ref47/cit47 ref1/cit1 ref44/cit44 ref7/cit7
References_xml	– ident: ref37/cit37 doi: 10.3233/JAD-143120 – ident: ref42/cit42 doi: 10.3233/JAD-190817 – ident: ref8/cit8 doi: 10.1038/nature19323 – ident: ref13/cit13 doi: 10.1007/s13770-019-00226-7 – ident: ref2/cit2 doi: 10.1038/s41572-021-00269-y – ident: ref30/cit30 doi: 10.1016/j.nantod.2015.10.001 – ident: ref34/cit34 doi: 10.1016/j.bone.2003.07.005 – ident: ref5/cit5 doi: 10.2174/15680266113139990135 – ident: ref31/cit31 doi: 10.1021/acsnano.6b02876 – ident: ref40/cit40 doi: 10.1073/pnas.1710329115 – ident: ref3/cit3 doi: 10.1038/s41573-022-00391-w – ident: ref41/cit41 doi: 10.1007/s12035-014-9070-5 – start-page: 115 volume-title: Laboratory Animal Welfare year: 2014 ident: ref21/cit21 doi: 10.1016/B978-0-12-385103-1.00009-9 – ident: ref47/cit47 doi: 10.1002/adma.202207719 – ident: ref14/cit14 doi: 10.1021/acs.nanolett.8b01816 – ident: ref10/cit10 doi: 10.1155/2021/7834421 – ident: ref43/cit43 doi: 10.1007/s12272-016-0799-4 – ident: ref38/cit38 doi: 10.1016/j.bbrc.2017.08.115 – ident: ref50/cit50 doi: 10.3389/fimmu.2021.634119 – ident: ref17/cit17 doi: 10.1038/cdd.2011.140 – ident: ref48/cit48 doi: 10.1007/s12035-014-8811-9 – ident: ref11/cit11 doi: 10.1002/ame2.12207 – ident: ref18/cit18 doi: 10.1016/j.neurobiolaging.2010.03.024 – ident: ref36/cit36 doi: 10.1016/j.scr.2017.11.005 – ident: ref23/cit23 doi: 10.1186/s13287-021-02480-w – ident: ref33/cit33 doi: 10.1007/s10238-015-0375-0 – ident: ref1/cit1 doi: 10.1038/nrdp.2015.56 – ident: ref9/cit9 doi: 10.1038/s41591-021-01455-x – ident: ref32/cit32 doi: 10.1038/srep39340 – ident: ref24/cit24 doi: 10.1186/s13287-018-1007-x – ident: ref44/cit44 doi: 10.1016/j.febslet.2010.07.028 – ident: ref45/cit45 doi: 10.1007/s10787-019-00613-5 – ident: ref29/cit29 doi: 10.3389/fnins.2018.00632 – ident: ref15/cit15 doi: 10.1007/s13770-019-00234-7 – ident: ref20/cit20 doi: 10.1016/S0301-472X(03)00110-3 – ident: ref6/cit6 doi: 10.1038/s41582-018-0116-6 – ident: ref26/cit26 doi: 10.3892/mmr.2020.11102 – ident: ref7/cit7 doi: 10.1002/alz.12213 – ident: ref22/cit22 doi: 10.1016/j.jconrel.2020.02.035 – ident: ref39/cit39 doi: 10.1002/adma.202106516 – ident: ref12/cit12 doi: 10.1007/s13770-019-00233-8 – ident: ref28/cit28 doi: 10.1126/sciadv.aaz0952 – ident: ref25/cit25 doi: 10.1016/j.humpath.2006.01.022 – ident: ref16/cit16 doi: 10.4161/auto.26508 – ident: ref49/cit49 doi: 10.3389/fnagi.2017.00204 – ident: ref19/cit19 doi: 10.3233/JAD-200219 – ident: ref4/cit4 doi: 10.1016/j.jalz.2010.04.006 – ident: ref46/cit46 doi: 10.1186/1742-2094-11-98 – ident: ref35/cit35 doi: 10.15283/ijsc18034 – ident: ref27/cit27 doi: 10.1021/acs.nanolett.8b01816
SSID	ssj0009350
Score	2.5157619
Snippet	Alzheimer’s disease (AD) is a neurodegenerative disease with multifactorial pathogenesis. However, most current therapeutic approaches for AD target a single... Alzheimer's disease (AD) is a neurodegenerative disease with multifactorial pathogenesis. However, most current therapeutic approaches for AD target a single...
SourceID	proquest pubmed crossref acs
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	476
SubjectTerms	Aged Alzheimer Disease - metabolism Alzheimer Disease - therapy Animals Cell Differentiation Humans Magnetic Iron Oxide Nanoparticles Mesenchymal Stem Cells Mice Neurodegenerative Diseases Wharton Jelly
Title	Iron Oxide Nanoparticle-Incorporated Mesenchymal Stem Cells for Alzheimer’s Disease Treatment
URI	http://dx.doi.org/10.1021/acs.nanolett.2c03682 https://www.ncbi.nlm.nih.gov/pubmed/36638236 https://www.proquest.com/docview/2765779426
Volume	23
WOSCitedRecordID	wos000920395300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVABC databaseName: American Chemical Society Journals customDbUrl: eissn: 1530-6992 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009350 issn: 1530-6984 databaseCode: ACS dateStart: 20010101 isFulltext: true titleUrlDefault: https://pubs.acs.org/action/showPublications?display=journals providerName: American Chemical Society
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3JSgQxEA1uBz24L-NGBC8eonZ6yxyHUdGDC6gwtyZJJczATI9Mt6Ke_A1_zy-x0osbiHhtkpC16lVX8h4huzFoawPtM8ulZEHTApNCSQaAzgpdEnhKF2IT8cWF6HSaV5-B4s8MPvcOpM72U5kOcRj5PtdocQWa3EmOSNdd4Wu1rz9Jdv1CkRUPMYZETRHUT-V-acU5JJ19d0i_oMzC25zM_bef82S2wpW0VW6EBTJm0kUy84VtcIkkZ6NhSi8fe2AoGlWMlsvC7MxxWRZ8xgbouXuOpLtPA2ztOjcD2jb9fkYR29JW_7lregMzent5zehRmdqhN_VV9WVye3J80z5llb4Ck34gciZ0yFUgwJhAYhylfOAG0F3HViknK4nozHHvKERQ3LPQxFUFCDVaAM_6JhT-CplIh6lZIzSIwEY25nAoIIhMJA4l4jajtLIaIRE0yB7OT1KdjywpUt_cS9zHetKSatIaxK8XJNEVUbnTy-j_UYt91LoriTr-KL9Tr3WCJ8qlSWRqhvdZwuMojNFM8ahBVstN8NGijwDNScSv_2M8G2TaadS7_zY83CQT-ejebJEp_ZD3stE2GY87YrvYx--Kw_TW
linkProvider	American Chemical Society
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LTxsxEB4hitT2QOk7tFBX6qUHF9b7co5RWkRUSCuRStws22OLSMmmyi4V5cTf4O_1l3S8DygHhMrVskd-znzeWX8fwIccrfeJjbkXWvOk75FraTRHpGBFIQkjY2uxiXw8lsfH_e8rkHZvYagTJVkq6yT-NbtAtBPKCl0saDTVJ2HJ8UryvA9SirBBuGAwPLrm2o1rYVY6y3Qz6sukezF3i5UQl2x5My7dAjbroLP35J7d3YD1FmWyQbMtnsKKK57B43-4B5-DGi0XBft2NkXHyMXS3bmpzEeB2bJmN3bIDsPjJHvye07Wjio3Z0M3m5WMkC4bzM5P3HTuln8uLkv2uUn0sEn34_oL-LH3ZTLc563aAtdxIisubSpMItG5RNOtysQoHFLwzr0xQWSSsFpg4jGEp0TksU9rjJha8geRj10q45ewWiwK9xpYkqHPfC5wV2KSuUzuakJxzljjLQEk7MFHmh_VnpZS1YlwEalQ2E2aaietB3G3Lsq2tOVBPWN2Ryt-1epnQ9txR_333ZIrOl8haaILtzgtlcizNCenJbIevGr2wpXFmOBaEIzf_I_xvIOH-5PDA3UwGn99A4-Cen34oiPSt7BaLU_dFqzZX9W0XG7Xm_ovQrP8VA
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3LThsxFLUQIFQWFGiBUCiuxKYLF8bzcpZRICKCpkiAxM6yfW0RKZmgzICAFb_B7_VLej0PCguEqm4t-8qve-_xeHwOIbspGOciEzLHlWJR2wFTQisGgMkKUxIE2pRiE-lgIC4v26cvpL6wEzlaystLfO_V1-BqhoFgz5dnKpvgiIof3GDwFRh952LM6V68oNM9-8u3G5birOjPeDpqi6h5NfeGFZ-bTP46N70BOMvE0_v4H11eJks12qSdanuskBmbrZLFFxyEn4jsTycZ_XU3BEsx1OIZuqrM-p7hsmQ5tkB_-kdK5up-jNbOCjumXTsa5RQRL-2MHq7scGynvx-fcnpQXfjQ8-YH9s_kond43j1iteoCU2EkCiZMzHUkwNpI4elKh8AtYBJPndZebBIxm2fk0YireOCgjWsNEBuMC4ELbSzCNTKbTTK7QWiUgEtcymFfQJTYROwrRHNWG-0MAiVoke84P7L2mlyWF-I8kL6wmTRZT1qLhM3aSFPTl3sVjdE7rdhzq-uKvuOd-t-aZZfoZ_7yRGV2cpNLniZxisGLJy2yXu2HZ4shwjYvHL_5D-PZIQunBz150h8cfyEfvIi9_7DD4y0yW0xv7DaZN7fFMJ9-Lff1HzlB_s4
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Iron+Oxide+Nanoparticle-Incorporated+Mesenchymal+Stem+Cells+for+Alzheimer%E2%80%99s+Disease+Treatment&rft.jtitle=Nano+letters&rft.au=Jung%2C+Mungyo&rft.au=Kim%2C+Hyeongseop&rft.au=Hwang%2C+Jung+Won&rft.au=Choi%2C+Yejoo&rft.date=2023-01-25&rft.pub=American+Chemical+Society&rft.issn=1530-6984&rft.eissn=1530-6992&rft.volume=23&rft.issue=2&rft.spage=476&rft.epage=490&rft_id=info:doi/10.1021%2Facs.nanolett.2c03682&rft.externalDocID=i57391457
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1530-6984&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1530-6984&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1530-6984&client=summon